Literature DB >> 20130058

The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the Cbl-CIN85 complex.

Vivek Chandra1, Manjula Kalia, Krishnan Hajela, Shahid Jameel.   

Abstract

Hepatitis E virus (HEV) causes an acute self-limiting disease that is endemic in developing countries. Previous studies suggested that the ORF3 protein (pORF3) of HEV is required for infection in vivo and is likely to modulate the host response. Our previous work showed that pORF3 localizes to early and recycling endosomes and causes a delay in the postinternalization trafficking of epidermal growth factor receptor (EGFR) to late endosomes/lysosomes. Here we report that pORF3 also delays the trafficking and degradation of activated hepatocyte growth factor receptor (c-Met) and delineate the mechanistic details of these effects. A mutant ORF3 protein, which does not localize to endosomes, also showed similar effects on growth factor receptor trafficking, making this effect independent of the endosomal localization of pORF3. The ORF3 protein was found to interact with CIN85, a multidomain adaptor protein implicated in the Cbl-mediated downregulation of receptor tyrosine kinases. This interaction competed with the formation of the growth factor receptor-Cbl-CIN85 complex, resulting in the reduced ubiquitination of CIN85 and trafficking of the growth factor receptor complex toward late endosomes/lysosomes. We propose that through its effects on growth factor receptor trafficking, pORF3 prolongs endomembrane growth factor signaling and promotes cell survival to contribute positively to viral replication and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130058      PMCID: PMC2849493          DOI: 10.1128/JVI.01994-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors.

Authors:  Katarzyna Kowanetz; Iwona Szymkiewicz; Kaisa Haglund; Marcin Kowanetz; Koraljka Husnjak; Jonathan D Taylor; Philippe Soubeyran; Ulla Engstrom; John E Ladbury; Ivan Dikic
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

2.  CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors.

Authors:  Katarzyna Kowanetz; Koraljka Husnjak; Daniela Höller; Marcin Kowanetz; Philippe Soubeyran; Dianne Hirsch; Mirko H H Schmidt; Kresimir Pavelic; Pietro De Camilli; Paul A Randazzo; Ivan Dikic
Journal:  Mol Biol Cell       Date:  2004-04-16       Impact factor: 4.138

3.  ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro.

Authors:  Suzanne U Emerson; Hanh Nguyen; Udana Torian; Robert H Purcell
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 4.  The EGFR as a target for viral oncoproteins.

Authors:  W E Miller; N Raab-Traub
Journal:  Trends Microbiol       Date:  1999-11       Impact factor: 17.079

5.  The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton.

Authors:  M Zafrullah; M H Ozdener; S K Panda; S Jameel
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 6.  Hepatitis E.

Authors:  K Krawczynski
Journal:  Hepatology       Date:  1993-05       Impact factor: 17.425

7.  Epidermal growth factor induces ubiquitination of Eps15.

Authors:  S van Delft; R Govers; G J Strous; A J Verkleij; P M van Bergen en Henegouwen
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

8.  Herpes simplex virus 1 infected cell protein 0 forms a complex with CIN85 and Cbl and mediates the degradation of EGF receptor from cell surfaces.

Authors:  Yu Liang; Alexei Kurakin; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-11       Impact factor: 11.205

9.  Hepatitis E virus transmission to a volunteer.

Authors:  A Chauhan; S Jameel; J B Dilawari; Y K Chawla; U Kaur; N K Ganguly
Journal:  Lancet       Date:  1993-01-16       Impact factor: 79.321

Review 10.  Molecular biology and pathogenesis of hepatitis E virus.

Authors:  Vivek Chandra; Shikha Taneja; Manjula Kalia; Shahid Jameel
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

View more
  26 in total

1.  Full-length sequence analysis of hepatitis E virus isolates: showing potential determinants of virus genotype and identity.

Authors:  Dong Yang; Mei Jiang; Min Jin; Zhigang Qiu; Weihong Cui; Zhiqiang Shen; Bo Li; Lianfeng Gong; Zhaoli Chen; Xinwei Wang; Jun-Wen Li
Journal:  Virus Genes       Date:  2013-07-26       Impact factor: 2.332

2.  The PSAP motif within the ORF3 protein of an avian strain of the hepatitis E virus is not critical for viral infectivity in vivo but plays a role in virus release.

Authors:  Scott P Kenney; R S Pudupakam; Yao-Wei Huang; F William Pierson; Tanya LeRoith; Xiang-Jin Meng
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Hepatitis E virus replication requires an active ubiquitin-proteasome system.

Authors:  Yogesh A Karpe; Xiang-Jin Meng
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

Review 4.  Hepatitis E virus: advances and challenges.

Authors:  Ila Nimgaonkar; Qiang Ding; Robert E Schwartz; Alexander Ploss
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-22       Impact factor: 46.802

Review 5.  Hepatitis E Virus Genome Structure and Replication Strategy.

Authors:  Scott P Kenney; Xiang-Jin Meng
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

Review 6.  Therapeutic targets for the treatment of hepatitis E virus infection.

Authors:  Scott P Kenney; Xiang-Jin Meng
Journal:  Expert Opin Ther Targets       Date:  2015-06-13       Impact factor: 6.902

7.  Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation.

Authors:  Laura Córdoba; Yao-Wei Huang; Tanja Opriessnig; Kylie K Harral; Nathan M Beach; Carla V Finkielstein; Suzanne U Emerson; Xiang-Jin Meng
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

8.  Construction of an infectious cDNA clone of avian hepatitis E virus (avian HEV) recovered from a clinically healthy chicken in the United States and characterization of its pathogenicity in specific-pathogen-free chickens.

Authors:  Hyuk Moo Kwon; Tanya LeRoith; R S Pudupakam; F William Pierson; Yao-Wei Huang; Barbara A Dryman; Xiang-Jin Meng
Journal:  Vet Microbiol       Date:  2010-07-22       Impact factor: 3.293

9.  Mutational analysis of the hypervariable region of hepatitis e virus reveals its involvement in the efficiency of viral RNA replication.

Authors:  R S Pudupakam; Scott P Kenney; Laura Córdoba; Yao-Wei Huang; Barbara A Dryman; Tanya Leroith; F William Pierson; Xiang-Jin Meng
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

10.  An ethanol extract of Lysimachia mauritiana exhibits inhibitory activity against hepatitis E virus genotype 3 replication.

Authors:  Seong Eun Jin; Jung-Eun Kim; Sun Yeou Kim; Bang Ju Park; Yoon-Jae Song
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.